Inflammatix, Inc.

United States - Sunnyvale, California

• 13/09/2024
• Series E
• $57,000,000

Inflammatix is developing an innovative point-of-care instrument platform to be used with a test to aid in the diagnosis of acute infection and sepsis by harnessing the immune system to deliver advanced immune response diagnostics. Our test rapidly informs the clinician about the likelihood of bacterial or viral infection and the need for ICU level care in the emergency department. Faster results may translate into more timely and appropriate therapy and level of care decisions.

*Products in development, are not for sale, and do not have marketing approval or clearance from regulatory authorities in any jurisdiction.

Related People

Tim SweeneyCo Founder

United States - Sunnyvale, California

As the co-founder and CEO of Inflammatix, I lead a molecular diagnostics startup that leverages machine learning and immune system 'big data' to create novel clinical diagnostics. I have a strong background in medicine, data science/ML, and building health technologies, with an MD, PhD, and time spent practicing as a surgeon in residency.

My mission is to revolutionize the diagnosis and treatment of acute infections and critical illnesses, and to reduce the global threat of antibiotic resistance. Inflammatix is developing rapid, point-of-care tests that can accurately identify the type and severity of infections, and guide optimal antibiotic therapy. Our tests have the potential to save thousands of lives, improve patient outcomes, and lower health system costs. I am also passionate about mentoring and investing in early-stage startups in the biotech and medtech sectors, and I serve as a steering committee member at the Sepsis Innovation Council and a neighborhood lead at StartX.

LinkedIn https://www.linkedin.com/in/tim-sweeney-a6589594/